In Colorectal Cancer, Chemo-Induced Volume Elevation Linked with Postoperative Complications
the Cancer Therapy Advisor take:
According to a new study published in the Journal of the American College of Surgeons, researchers have found that having liver metastases and receiving chemotherapy are associated with higher splenic volume in patients with metastatic colorectal cancer, and the splenic volume increase is independently linked with major postoperative complications following hepatic resection.
For the study, researchers enrolled 80 patients with metastatic colorectal cancer and liver metastases who underwent hepatic resection. Of those, half received chemotherapy for 6 months before surgery while the other half did not receive preoperative chemotherapy. The patients who received preoperative chemotherapy were also compared to a group of 40 patients with benign disease who underwent cholecystectomy and a group of 40 patients with untreated non-metastatic colorectal cancer.
Results showed that the study group had significantly higher splenic volumes compared with the patients with benign disease (p < 0.001) and the patients with non-metastatic disease (p < 0.05) before chemotherapy. After 6 months of chemotherapy, the study group's splenic volumes were even higher, and the elevation was linked with any complication during surgery (p < 0.01) and major postoperative complications (p < 0.05).
Furthermore, patients with a 39% or higher increase in splenic volume were statistically significantly more likely to develop major complications after hepatic resection (p < 0.01). Of note, the researchers found no association between splenic volume increase and change in platelet count.
Splenic volume increase is independently linked with major postoperative complications following hepatic resection.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Calcium and Cancer
- Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths
- Atezolizumab Monotherapy Effective in PD-L1 Non-small Cell Lung Cancer
- Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma
- Cabozantinib Effective as Salvage Therapy in Thyroid Cancer
- Everolimus Maintains Quality of Life in Neuroendocrine Tumors
- High Dose Vitamin B Supplements Should Not Be Taken for Lung Cancer Prevention
- Telomere Length May Predict Renal Cell Carcinoma Risk in Patients with VHL
- Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse
- Identifying Frail Patients With Multiple Myeloma Improves Treatment Selection